Analyst Ratings For Allogene Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Allogene Therapeutics (NASDAQ:ALLO) over the past three months, with a recent positive shift in the average 12-month price target. The company's financials show challenges, including a significant decline in revenue growth and negative net margins, but it maintains strong ROE and ROA.
May 31, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts have mixed ratings for Allogene Therapeutics, with a recent positive shift in the average 12-month price target to $10.66. The company's financials show a decline in revenue growth and negative net margins, but strong ROE and ROA.
The mixed analyst ratings and recent positive shift in price targets suggest a neutral short-term impact on the stock. While financial challenges are evident, strong ROE and ROA provide some positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100